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into the US marketplace. METHODS: Generic ﬂuoxetine
became available in August 2001. Pharmacy claims 
data from January 2000 to December 2002 were used 
to analyze utilization of the SSRI class (consisting of the
following: Celexa, Zoloft, Paxil, Effexor XR, Prozac, 
and ﬂuoxetine). Utilization data for each drug in the class
were separated into two group periods, pre- and post
introduction of generic ﬂuoxetine. The pre- and post
periods consisted of 19 and 17 months respectively. Uti-
lization of Prozac and ﬂuoxetine was used as a reference
to compare utilization of other drugs in the class. T-test
analysis was used to compare and show differences
between pre- and post-periods for each drug. RESULTS:
Prozac/ﬂuoxetine average monthly prescription utiliza-
tion for pre- and post-periods were 3434.16 and 4349.56
respectively (p < 0.001), which indicates an average
increase in monthly utilization by 27%. Celexa average
monthly utilization for pre- and post-periods were
1252.95 and 2848.4 respectively (p < 0.001), demon-
strating an increase in utilization by 127%. Effexor XR
average monthly utilization during pre- and post-periods
were 908.58 and 2084.38 respectively (p < 0.001), indi-
cating an increase of 129%. Paxil average monthly uti-
lization for pre- and post periods were 2834.9 and 4059.6
respectively (p < 0.001), indicating an increase of 43%.
Lastly, Zoloft’s average monthly utilization for pre- and
post periods were 3915.05 and 4615.88 respectively 
(p < 0.001), which resulted in an increase of 18%. 
CONCLUSION: In this managed care setting a signiﬁ-
cant increase in monthly utilization was seen for all drugs
with the exception of Zoloft.
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OBJECTIVES: Adopting new medical therapies is a
complex decision that must take into account many
factors, including differences in efﬁcacy, tolerability,
safety, and costs. Long-term comparative trials, especially
among newer antiepileptic drugs (AEDs), are lacking,
therefore decision models are needed to guide treatment
decisions. We aimed to develop an economic model of the
treatment of refractory epilepsy in the UK, and to assess
the cost-effectiveness of topiramate as adjunctive treat-
ment in refractory epilepsy compared to other newer
AEDs. METHODS: A Markov model was developed to
combine data from published clinical trials, cost-of illness
studies, epilepsy-related mortality surveys, and utility
studies. The expected costs and utilities associated with
possible treatment strategies (1st and 2nd line add-on
treatments) for newly diagnosed epilepsy patients with
partial seizures were calculated and compared. In those
patients requiring a second-line add-on, it was assumed
that the ﬁrst-line add-on treatment was stopped. A 
probabilistic analysis was undertaken and the cost-
effectiveness frontier mapped. RESULTS: First and
second-line adjunctive treatment with topiramate fol-
lowed by levetiracetam was the least costly add-on strat-
egy, and this strategy had the highest probability of being
cost-effective at currently accepted values of the ceiling
ratio (<£30,000/QALY). Levetiracetam ﬁrst-line, fol-
lowed by topiramate second-line generated additional
QALYs, but was more expensive, and was optimal only
if the ceiling ratio fell between £30,000 to £60,000/
QALY. Scenarios combining sequences of topiramate and
lamotrigine deliver a few additional QALYs at substan-
tial additional costs (became optimal only if the ceiling
ratio was >£60,000/QALY), while adjunctive treatment
with levetiracetam and lamotirigine are both more expen-
sive and generate less QALYs than the other scenarios,
therefore cannot be preferred. CONCLUSIONS: This
model suggests that topiramate ﬁrst-line adjunctive treat-
ment followed by levetiracetam second-line (or vice versa)
are cost-effective treatment strategies in patients with
partial seizures refractory to other treatments.
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OBJECTIVES: As sales of anti-migraine prescription
medications increased by more than 10-fold between
1994 and 1999, it is important to quantify the impact on
the cost of migraine treatment. The objectives of this
study were to determine the direct costs of migraine in
the U.S. population and to stratify those costs by type of
medical care. METHODS: Retrospective analysis was
conducted of the 1999 Medical Expenditure Panel Survey.
The survey provided data from a nationally representa-
tive sample of 24,618 respondents and their medical care
and health insurance providers. Data utilized in this study
included medical conditions and use and payments for
medical care. Migraineurs were identiﬁed using ICD-9-
CM codes and direct costs were calculated using patient
and third-party payments for migraine related medical
events by type of medical care. Sample estimates were
projected to the population and 95% conﬁdence limits
were calculated using the Taylor expansion method.
RESULTS: Direct costs incurred per migraineur were
$293. Total direct costs of migraine were
$1,429,053,413. The highest proportion of these costs
